ArticleJournal of periodontology2026
A retrospective cohort study comparing periodontal regeneration using fibroblast growth factor-2 versus autologous bone graft.
Article in Journal of periodontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical efficacy of different biomaterials for the regenerative treatment of periodontal intrabony defects: a systematic review and Bayesian network meta-analysis.BMC oral health · 2026Pooled it
- A retrospective cohort study comparing periodontal regeneration using fibroblast growth factor-2 versus autologous bone graft.Journal of periodontology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFibroblast growth factor-2 (FGF-2) is a novel agent utilized in periodontal regeneration therapy. However, its clinical efficacy compared with autologous bone graft (ABG), a long-established treatment, remains unclear. This study aimed to compare the clinical outcomes of FGF-2 and ABG and to assess the impact of patient background factors on outcomes when using FGF-2.
methodsWe collected the subjects from January 2013 to September 2023. Clinical outcomes included the vertical bone defect improvement rate (VBDIR) and the probing pocket depth improvement (PPDI). Clinical outcomes between the two groups were compared using analysis of covariance (ANCOVA), adjusting for age, sex, smoking history, and hypertension. Additionally, a multilevel linear analysis was performed to assess factors influencing outcomes in FGF-2.
resultsA total of 180 sites from 141 patients (FGF-2: 150 sites; ABG: 30 sites) were evaluated. Both VBDIR and PPDI significantly improved postoperatively in both groups. There were no significant differences in clinical outcomes between FGF-2 and ABG. In FGF-2, smoking history was positively associated, while the preoperative bone defect angle (BDA) was negatively associated with clinical outcomes.
conclusionsFGF-2 might exhibit clinical outcomes comparable to those of ABG, suggesting it is a clinically viable alternative for vertical bone defects. When using FGF-2, patient-specific factors such as smoking history and preoperative BDA should be considered carefully. THE NAME IN THE TRIAL REGISTRY: A survey of clinical practice and evaluation of treatment outcomes of periodontal regenerative therapy using REGROTH at Okayama University Hospital PLAIN LANGUAGE SUMMARY: This retrospective study compared the clinical outcomes of fibroblast growth factor-2 (FGF-2), a novel therapeutic agent, with autologous bone graft (ABG), a long-established treatment. A total of 180 sites from 141 patients (150 FGF-2 sites, 30 ABG sites) were evaluated based on the vertical bone defect improvement rate (VBDIR) and the probing pocket depth improvement (PPDI). Using analysis of covariance (ANCOVA), adjusted for patient background factors such as age, sex, smoking history, and hypertension, no significant differences in clinical outcomes were observed between the two treatment groups. Further multilevel linear analysis focusing on the FGF-2 group revealed that smoking history was positively associated, while preoperative bone defect angle (BDA) was negatively associated with clinical outcomes. These findings suggest that FGF-2 may offer clinical benefits comparable to ABG in treating vertical bone defects while having the added advantage of being less invasive. However, when using FGF-2, dentists should consider individual patient factors such as smoking habits and defect morphology, as these may influence treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.